352 related articles for article (PubMed ID: 31594641)
1. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
2. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
Dow EC; Liu H; Rice AP
J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
[TBL] [Abstract][Full Text] [Related]
3. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
4. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
Zhou M; Huang K; Jung KJ; Cho WK; Klase Z; Kashanchi F; Pise-Masison CA; Brady JN
J Virol; 2009 Jan; 83(2):1036-44. PubMed ID: 18971272
[TBL] [Abstract][Full Text] [Related]
6. Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis.
Lin Z; Li S; Sheng H; Cai M; Ma LY; Hu L; Xu S; Yu LS; Zhang N
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2469-2478. PubMed ID: 27601167
[TBL] [Abstract][Full Text] [Related]
7. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
[TBL] [Abstract][Full Text] [Related]
8. RNA polymerase II transcription elongation and Pol II CTD Ser2 phosphorylation: A tail of two kinases.
Bowman EA; Kelly WG
Nucleus; 2014; 5(3):224-36. PubMed ID: 24879308
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
10. A Cdk9-PP1 switch regulates the elongation-termination transition of RNA polymerase II.
Parua PK; Booth GT; Sansó M; Benjamin B; Tanny JC; Lis JT; Fisher RP
Nature; 2018 Jun; 558(7710):460-464. PubMed ID: 29899453
[TBL] [Abstract][Full Text] [Related]
11. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
[TBL] [Abstract][Full Text] [Related]
13. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
[TBL] [Abstract][Full Text] [Related]
14. c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren AO; Oehler C; Shalaby T; von Hoff K; Pruschy M; Seifert B; Gerber NU; Warmuth-Metz M; Stearns D; Eberhart CG; Kortmann RD; Rutkowski S; Grotzer MA
BMC Cancer; 2011 Feb; 11():74. PubMed ID: 21324178
[TBL] [Abstract][Full Text] [Related]
15. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
Walsby E; Pratt G; Shao H; Abbas AY; Fischer PM; Bradshaw TD; Brennan P; Fegan C; Wang S; Pepper C
Oncotarget; 2014 Jan; 5(2):375-85. PubMed ID: 24495868
[TBL] [Abstract][Full Text] [Related]
16. In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Craveiro RB; Ehrhardt M; Holst MI; Pietsch T; Dilloo D
Oncotarget; 2014 Aug; 5(16):7149-61. PubMed ID: 25216529
[TBL] [Abstract][Full Text] [Related]
17. Herpes Simplex Virus 1 (HSV-1) ICP22 protein directly interacts with cyclin-dependent kinase (CDK)9 to inhibit RNA polymerase II transcription elongation.
Zaborowska J; Baumli S; Laitem C; O'Reilly D; Thomas PH; O'Hare P; Murphy S
PLoS One; 2014; 9(9):e107654. PubMed ID: 25233083
[TBL] [Abstract][Full Text] [Related]
18. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
19. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ; Welsh SA; Devlin JR; Barbieri E; Knight DA; Offley S; Bjelosevic S; Costacurta M; Todorovski I; Kearney CJ; Sandow JJ; Fan Z; Blyth B; McLeod V; Vissers JHA; Pavic K; Martin BP; Gregory G; Demosthenous E; Zethoven M; Kong IY; Hawkins ED; Hogg SJ; Kelly MJ; Newbold A; Simpson KJ; Kauko O; Harvey KF; Ohlmeyer M; Westermarck J; Gray N; Gardini A; Johnstone RW
Cell; 2021 Jun; 184(12):3143-3162.e32. PubMed ID: 34004147
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
